- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03288610
Prediction of Inflammatory Response and Hypotensive Syndrome After Cardiac Surgery by Preoperative Copeptin Level (MicorSIRS)
Prognostic Value of Copeptin Level Before Cardiac Surgery and Involvement in Systemic Inflammatory Response Syndrome After Cardiopulmonary Bypass
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The occurrence of a severe systemic inflammatory response syndrome (SIRS) after elective cardiac surgery with cardiopulmonary bypass (CPB) is estimated at about 20% of cases and is characterized by hemodynamic changes (tachycardia, hypotension, hypovolemia). It is also responsible for vasodilation with impaired microcirculation involving increased morbidity and mortality associated with organ dysfunction and the risk of bacterial translocation. However, the participation of vasopressinergic system in the functional impairment of microcirculation is unclear.
Copeptin is considered a marker of vasopressin secretion, deriving from the same precursor, being more stable and easy to dose. In a previous study of 64 patients with CPB, the investigators have shown that high copeptin preoperative levels are associated with the occurrence of vasodilatation syndrome after cardiac surgery (incidence 15%) with a relative deficiency of postoperative vasopressin.
Microcirculatory alterations can be explored through the study of tissue oxygenation by NIRS (StO2) at rest and in response to a hypoxic challenge (provided by brief vascular occlusion). In septic shock, altered recovery slopes of tissue oxygenation are associated with poor prognosis. The investigators could find similar impact on prognosis in cardiogenic shock if first hours of care did not improve this recovery slope.
The investigators hypothesize that an increase of the preoperative stimulation of vasopressinergic system (in response to acute or chronic conditions) could favor the occurrence of vasodilatation during and after CPB and increase the symptoms of an inflammatory response after CPB. The involvement of vasopressin in microcirculatory dysfunction is unknown.
This is a validation study of a predictive test for pathophysiology and prognosis. This study will be monocentric, prospective and observational in routine care.
The main end point of the study is to predict the onset of severe SIRS or postoperative vasodilation syndrome after CPB by the preoperative plasma copeptin level in a cardiac surgery population.
The secondary objectives are to assess the incidences of microcirculatory dysfunction, shock and organs failure after CPB, to determine the postoperative copeptin kinetics for patients with severe SIRS, to evaluate the prognosis with the ICU length of stay and D28 mortality.
Data are recorded prospectively on a paper case report form by ICU physicians in charge of the patients on the basis of clinical observation and electronic medical records. Quality assurance, monitoring and auditing are provided by the study promotor. Data will be checked by the main investigator to assess the accuracy and completeness of entered data into the CRF.
Patients are recruited during the preoperative period after screening of inclusion and exclusion criteria, delivering information and obtaining written consent.
Considering an expected sensitivity for predicting SIRS by preoperative copeptin on the order of 80%, the number of cases (subjects with severe SIRS) to be included for obtaining an estimate of the sensitivity with a lower limit of 95% to 55% is placed in 42 cases. Considering an incidence of severe SIRS at 20%, the total number of patients to be included in the study is 200. In our center the investigators perform 700 CPB / year, 70% met the criteria for inclusion.
For the primary objective, the predictive performance of preoperative copeptin for the occurrence of post-CPB severe SIRS will be evaluated by the construction of a ROC curve with finding an optimal threshold maximizing sensitivity and specificity (calculation of the Youden index) to be then estimated with their 95% confidence interval.
Regarding the secondary objectives, copeptin levels will be compared according to the presence of postoperative microcirculatory dysfunction, hemodynamic failure, organ dysfunction and preoperative factors using a reduced gap test. Univariate and multivariate analysis using linear regressions will be carried out to find the preoperative factors associated significantly and independently to high copeptin level. The postoperative kinetics of copeptin will be modeled using mixed linear regressions with an intercept +/- a random slope and taking into account the intra-individual correlation of the assays. The prognostic value of preoperative copeptin and postoperative StO2 recovery slope on D28 mortality will be analyzed using the ROC curve, determination of an optimal threshold using the Youden index and then calculating Sensitivity and specificity with their 95% confidence interval.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34295
- Department of critical care, Arnaud de Villeneuve Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Elective surgery
- Scheduled time of at least 24 hours
- Cardiopulmonary bypass
Exclusion Criteria:
- Urgent surgery within 24 hours of hospital admission
- Chronic renal failure with preoperative glomerular filtration rate below 45 ml/min
- Ongoing sepsis (ie uncontrolled endocarditis)
- Immunosuppressive therapy (solid organ transplant recipient)
- Previously included in this study
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
With inflammatory response
Patients with postoperative inflammatory response as defined by the occurrence of severe SIRS and/or postoperative vasodilation syndrome. Severe SIRS is defined by meeting at least 2 SIRS criteria during 6 consecutive hours or at least 3 SIRS criterias. Classical SIRS criteria include: temperature >38,3 or <36°C, heart rate >90/min, respiratory rate >20/min or PaCO2 <32mmHg, GB>12000 ou <4000 c/mm3. Postoperative vasodilation syndrome is defined by the need of continuous infusion of norepinephrine (whatever the dose) to maintain the mean arterial pressure above 60 mmHg associated to a cardiac index above or egal to 2.2 L/min/m2. Patients without postoperative severe SIRS and without postoperative vasodilation syndrome |
Measure of plasmatic copeptin from preoperative samples retained in a biorepository.
Physicians are blinded to the result.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preoperative copeptin level
Time Frame: Preoperative 24 hours
|
Plasmatic copeptine will be measured from routine blood sample on heparinazed tubes.
The biological assay will be performed by Time-Resolved Amplified Cryptate Emission on automate Kryptor Compact plus (ThermoFisher, Clichy, France).
A level above the 97° percentile of referent population will be considered pathological.
|
Preoperative 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postoperative microcirculatory impairment
Time Frame: Within 2h of admission in intensive care unit, before weaning of sedation and mechanical ventilation
|
Tissue oxygen saturation (STO2) measured at the thenar eminence by NIRS (Inspectra 650, Hutchinson Technologies) with application of a 3 min vascular occlusion test to measure the occlusion slope, the recovery slope and the hyperemic rebound.
Microcirculatory dysfunction is defined by a recovery slope below 3%/s.
|
Within 2h of admission in intensive care unit, before weaning of sedation and mechanical ventilation
|
Occurrence of SIRS using classical definition
Time Frame: First postoperative 24 hours
|
SIRS is classically defined when 2 of the following criteria are met together: temperature >38,3 or <36°C, heart rate >90/min, respiratory rate >20/min or PaCO2 <32mmHg, GB>12000 ou <4000 c/mm3.
|
First postoperative 24 hours
|
Postoperative hemodynamical impairment
Time Frame: First postoperative 24 hours
|
Occurrence of
|
First postoperative 24 hours
|
Perioperative copeptin kinetics
Time Frame: 24 hours before the operation until admission intensive care unit
|
Plasmatic copeptin will be measured from routine blood sample on heparinized tubes.
The biological assay will be performed by Time-Resolved Amplified Cryptate Emission on automate Kryptor Compact plus (ThermoFisher, Clichy, France).
A level above the 97° percentile of referent population will be considered pathological.
|
24 hours before the operation until admission intensive care unit
|
Perioperative copeptin kinetics
Time Frame: postoperative day
|
Plasmatic copeptin will be measured from routine blood sample on heparinized tubes.
The biological assay will be performed by Time-Resolved Amplified Cryptate Emission on automate Kryptor Compact plus (ThermoFisher, Clichy, France).
A level above the 97° percentile of referent population will be considered pathological.
|
postoperative day
|
Global organs dysfunction
Time Frame: First postoperative 24 hours
|
Assessed by the Sequencial Organ Failure Assessment (SOFA) score calculated at the postoperative day
|
First postoperative 24 hours
|
Lengh of mechanical ventilation
Time Frame: Up to 28 days
|
Length (hours) of postoperative invasive mechanical ventilation
|
Up to 28 days
|
Acute kidney injury
Time Frame: Up to 28 days
|
Defined and classified according to KDIGO criteria
|
Up to 28 days
|
Renal replacement therapy
Time Frame: Up to 28 days
|
Incidence of patients requiring renal replacement therapy in ICU due to postoperative acute kidney injury
|
Up to 28 days
|
Intensive Care Unit stay
Time Frame: through study completion, an average of 3 month
|
Length (days) of postoperative intensive care unit stay
|
through study completion, an average of 3 month
|
Hospital stay
Time Frame: through study completion, an average of 3 month
|
Length (days) of postoperative hospital stay before current care ward discharge (excluding rehabilitation time)
|
through study completion, an average of 3 month
|
Intensive Care Unit mortality rate
Time Frame: Up to 28 days
|
Intensive care unit mortality rate : death before ICU discharge
|
Up to 28 days
|
Day 28 mortality rate
Time Frame: Up to 28 days
|
Overall mortality rate at 28 days after surgery
|
Up to 28 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Philippe Gaudard, MD, Montpellier University Hospital
Publications and helpful links
General Publications
- MacCallum NS, Finney SJ, Gordon SE, Quinlan GJ, Evans TW. Modified criteria for the systemic inflammatory response syndrome improves their utility following cardiac surgery. Chest. 2014 Jun;145(6):1197-1203. doi: 10.1378/chest.13-1023.
- Colson PH, Bernard C, Struck J, Morgenthaler NG, Albat B, Guillon G. Post cardiac surgery vasoplegia is associated with high preoperative copeptin plasma concentration. Crit Care. 2011;15(5):R255. doi: 10.1186/cc10516. Epub 2011 Oct 25.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Kidney Diseases
- Urologic Diseases
- Inflammation
- Endocrine System Diseases
- Disease
- Shock
- Pituitary Diseases
- Syndrome
- Systemic Inflammatory Response Syndrome
- Diabetes Insipidus
- Physiological Effects of Drugs
- Natriuretic Agents
- Hemostatics
- Coagulants
- Vasoconstrictor Agents
- Antidiuretic Agents
- Vasopressins
Other Study ID Numbers
- 9754
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stress Response
-
Catholic University of the Sacred HeartCompleted
-
Hôpital le VinatierRecruiting
-
Ankara Medipol UniversityAtılım UniversityCompletedStress ResponseTurkey
-
National Cancer Institute, EgyptCompleted
-
United States Army Research Institute of Environmental...CompletedResponse to Severe StressUnited States
-
Assiut UniversityCompletedStress Response During Laryngoscopy IntubationEgypt
-
University of SurreyCompletedStress Response | Laparoscopy | Colorectal DiseaseUnited Kingdom
-
Istinye UniversityThe Scientific and Technological Research Council of TurkeyRecruitingHepatectomy | Transplantation | Stress Response | MusicTurkey
-
Tanta UniversityCompletedHemodynamic Stability | Analgesic Effects | Systemic Stress ResponseEgypt
-
United States Army Research Institute of Environmental...CompletedMitigation of Immune Function Decrements in Response to StressUnited States
Clinical Trials on Preoperative copeptin level
-
Istanbul Training and Research HospitalCompleted
-
Berker OkayCompletedVentilator Lung | Lobar Pneumonia | Bronchopneumonia | Lower Respiratory Tract and Lung InfectionsTurkey
-
Nova Scotia Health AuthorityNot yet recruiting
-
Federal University of Mato GrossoCompleted
-
Uppsala University HospitalRegion Stockholm; Capio Research FoundationCompleted
-
Centre Jean PerrinRecruiting
-
University of ValenciaHospital Politècnic i Universitari la Fe de ValènciaCompletedKnee OsteoarthritisSpain
-
University of AarhusAarhus University Hospital; Danish Cancer Society; University of Southern DenmarkCompletedHealth and Coping Undergoing Ovarian Cancer Surgery. | Cancer RehabilitationDenmark
-
University of Colorado, DenverCompleted